Menu Search
Equities

Immutep Ltd

IMM:ASX

Immutep Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.29
  • Today's Change0.02 / 7.41%
  • Shares traded3.99m
  • 1 Year change-2.44%
  • Beta2.0884
Data delayed at least 20 minutes, as of Nov 08 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Immutep Ltd's revenues fell -37.61% from 191.72k to 119.62k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 39.90m to a larger loss of 42.72m.
Gross margin--
Net profit margin-35,710.27%
Operating margin-42,137.64%
Return on assets-24.48%
Return on equity-26.21%
Return on investment-25.99%
More ▼

Cash flow in AUDView more

In 2024, Immutep Ltd increased its cash reserves by 31.09%, or 38.37m. Cash Flow from Financing totalled 95.18m or 79,568.69% of revenues. In addition the company used 34.82m for operations while cash used for investing totalled 21.02m.
Cash flow per share-0.0334
Price/Cash flow per share--
Book value per share0.1293
Tangible book value per share0.1237
More ▼

Balance sheet in AUDView more

Immutep Ltd has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 161.79m.
Current ratio18.25
Quick ratio--
Total debt/total equity0.0084
Total debt/total capital0.0083
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.